Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man

Kleine, Appie H.; Glatz, Jan F. C.; Nieuwenhoven, Frans A. van; Vusse, Ger J.

doi:10.1007/bf01270583

Cited by 227 publications

(71 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1991, this observation was confirmed in humans by Abe et al [73] and Tanaka et al [66] suggesting that human hFABP could be used as a good biological marker with high sensitivity and predictivity for the detection of myocardial infarction. Later studies confirmed this assumption [29, 56, 66,73,74,75,76]. hFABP is released in the blood stream early after symptom onset and can be detected after 20 min.…”

Section: Hfabp In Acute Myocardial Infarctionsupporting

confidence: 57%

“…hFABP is released in the blood stream early after symptom onset and can be detected after 20 min. The peak concentration is reached 3–5 h after the onset of chest pain and returned to normal baseline values within 20 h. Kleine et al [75] reported a sensitivity higher than 80% for the diagnosis of AMI in the 30–210 min after symptoms onset. In 2004, Chan et al [77] reported the results of a study conducted on 218 patients suspected of AMI presenting with chest pain at hospital admission.…”

Section: Hfabp In Acute Myocardial Infarctionmentioning

confidence: 99%

See 1 more Smart Citation

Heart Fatty Acid Binding Protein in the Diagnosis of Myocardial Infarction: Where Do We Stand Today?

Colli¹,

Josa²,

Pomar³

et al. 2006

Cardiology

View full text Add to dashboard Cite

Heart fatty acid binding protein (hFABP) is a novel small cytosolic protein that is abundant in the heart. It is highly cardiac-specific (i.e. expressed primarily in cardiac tissue), but is also expressed at low concentrations in tissues outside the heart. After myocardial ischemic damage, hFABP can be detected in the blood as early as 1–3 h after onset of chest pain, with peak values reached at 6–8 h and plasma levels returning to normal within 24–30 h. hFABP’s clinical diagnostic value is very limited in the presence of renal failure and skeletal muscle diseases as it is completely renally eliminated. In these conditions, the diagnosis of acute myocardial infarction (AMI) may be overestimated. The combination of initial hFABP release after symptom onset, rapid kidney clearance from the circulation and high cardiac specificity suggests great potential for clinical use. Serial measurements of hFABP in the first 24 h after onset of symptoms in AMI patients can: (a) identify patients who are susceptible to reperfusion strategies, (b) detect perioperative AMIs, (c) distinguish patients who reperfuse their infarct-related artery from those who do not, as early as 30 min after starting thrombolytic treatment, (d) detect re-infarction if it occurs within 10 h after symptom onset, and (e) permit an accurate estimation of myocardial infarct size providing important prognosis information.

show abstract

Section: Hfabp In Acute Myocardial Infarctionsupporting

confidence: 57%

Section: Hfabp In Acute Myocardial Infarctionmentioning

confidence: 99%

Heart Fatty Acid Binding Protein in the Diagnosis of Myocardial Infarction: Where Do We Stand Today?

Colli¹,

Josa²,

Pomar³

et al. 2006

Cardiology

View full text Add to dashboard Cite

show abstract

“…Both hFABP and myoglobin appear in substantial quantities in serum within 2–3 h of the onset of cardiac damage, whereas other cardiac proteins such as CK-MB and cTnT take at least 4 h to appear in serum [2, 30, 31]. It is possible that the value of F/M varies more rapidly depending on the condition of cardiac damage.…”

Section: Discussionmentioning

confidence: 99%

“…Van Nieuwenhoven et al [9]reported that the ratio of the concentrations of myoglobin over hFABP allowed discrimination of myocardial and skeletal muscle injuries. In addition, the concentration of hFABP has been proposed as an early marker for not only acute myocardial infarction [1, 2]but also detection and evaluation of myocardial damage in patients with heart failure [3, 4]. Taking these points into consideration, we hypothesized that the value of F/M, but not the concentration of hFABP or that of myoglobin alone, would be a useful marker for estimation of cardiac damage in hemodialysis patients.…”

Section: Discussionmentioning

confidence: 99%

“…It is thought to be the key fatty acid carrier protein in the cytosol and to be rapidly released from cells into the circulation after the onset of cell damage. The concentration of hFABP has been proposed as a promising early marker of acute myocardial infarction [1, 2]. It has also been reported that hFABP is a novel sensitive marker for the detection and evaluation of myocardial damage in patients with heart failure [3, 4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Ratio of Heart-Type Fatty Acid-Binding Protein to Myoglobin

et al. 2004

View full text Add to dashboard Cite

Background: The concentration of heart-type fatty acid-binding protein (hFABP), a promising novel marker for detection of acute or persistent myocardial damage, is significantly influenced by renal clearance and thus has limitations to its usefulness in patients with renal dysfunction. We evaluated whether the serum ratio of hFABP to myoglobin (F/M) might be a useful marker for assessing cardiac damage in hemodialysis patients. Methods: Serum hFABP and myoglobin were measured, and the value of F/M was calculated in 21 hemodialysis patients. Cardiac markers (cardiac troponin T [cTnT], atrial natriuretic peptide [ANP], and brain natriuretic peptide [BNP]) and echocardiographic indices (left ventricular end-diastolic dimension [LVDd], left ventricular mass index [LVMI], and inferior vena cava [IVC] dimension) were examined and compared with hFABP, myoglobin, and F/M ratios. Results: Serum hFABP and myoglobin levels were significantly elevated in hemodialysis patients and reduced by 30–40% during hemodialysis. The value of F/M after hemodialysis, but not the concentration of hFABP or myoglobin, had significant linear correlations with ANP, BNP, cTnT, LVDd, LVMI, and IVC. Conclusion: The value of F/M after hemodialysis, but not the concentration of hFABP itself, might be a newly useful marker for estimation of cardiac damage and volume overload in hemodialysis patients.

show abstract

Biochemical Markers of Acute Coronary Syndromes

Azzazy

Christenson

2000

Encyclopedia of Analytical Chemistry

View full text Add to dashboard Cite

The acute coronary syndromes (ACSs) are a continuum of myocardial ischemia ranging from angina, indicating reversible tissue damage, through frank myocardial infarction (MI) with extensive tissue necrosis. The mortality from acute MI in the USA alone is 500 000 deaths per year. New predictors of cardiovascular events, that are easily measurable, are needed to improve diagnostic strategies for treating ACS patients. Cardiac markers, proteins released from the injured myocardium into the circulation, are useful for the diagnosis of MI according to the World Health Organization (WHO) criteria. Troponins I and T have emerged as sensitive, more cardiac‐specific clinical indicators for MI diagnosis and for risk stratification. A new generation of biochemical markers for indicating plaque rupture, platelet reactivity, and early MI offers promise for better assessment of patient risk so that clinicians may intervene to avoid adverse outcomes. Other biochemical markers, including the acute phase reactants and markers of thrombosis, may become useful for identifying a patient's location on the ACS spectrum and consequently the risk of adverse events. This article describes the spectrum of ACS current and future biomarkers that are closely linked to the progression of cardiac injury from ACS, and various applications of biochemical markers in assessment of reinfarction, reperfusion, perioperative MI, risk stratification, guiding therapeutic intervention, and infarct sizing. Finally, an assessment of the importance of rapid testing, different triage strategies for chest pain patients, and new trends to reduce the overall costs of patient hospitalization are discussed. The recommendations of the National Academy of Clinical Biochemistry for use of cardiac markers are also presented.

show abstract

Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man

Cited by 227 publications

References 26 publications

Heart Fatty Acid Binding Protein in the Diagnosis of Myocardial Infarction: Where Do We Stand Today?

Heart Fatty Acid Binding Protein in the Diagnosis of Myocardial Infarction: Where Do We Stand Today?

Serum Ratio of Heart-Type Fatty Acid-Binding Protein to Myoglobin

Biochemical Markers of Acute Coronary Syndromes

Contact Info

Product

Resources

About